as of 2024, it has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the United Kingdom or European Union
The 30mg format is the best-value option for Australian researchers running extended-duration cohorts: at the 4mg/week Phase 2 maintenance dose, a single 30mg vial supplies 7.5 weeks of research
Abnormal bleeding is bleeding that is not regular, lasts longer, or is heavier than usual
All these data suggest that iHLOs at Day 30 is in the peak of functional maturation
In the UK, prescribing decisions are guided by the specific licensed indication, patient preference, clinical circumstances, and local formulary recommendations
UK National Health Service (NHS)